NASDAQ:INDP
Indaptus Therapeutics, Inc.
Indaptus Therapeutics, Inc. reported net income of −$20.8M in fiscal 2025. The diluted share count rose 189.1%.Summary generated from Indaptus Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−587.6%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+189.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −8 | −15 | −16 | −15 | −20 |
| Net income | −8 | −14 | −15 | −15 | −21 |
| Free cash flow | −11 | n/a | n/a | n/a | n/a |
Recent filings
- 8-KEntry into a material agreement
Sep 30, 2026 - 8-KEntry into a material agreement
Sep 10, 2026 - 8-K/AAmended entry into a material agreement
Sep 8, 2026 - 8-KDirector or officer change
Sep 4, 2026 - 8-KEntry into a material agreement
Sep 1, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of operations and financial condition
Aug 13, 2026 - DEF 14AProxy statement
Jul 16, 2026